Loading
Loading
Research Overview
Synthetic hexapeptides that mimic ghrelin and activate GHS-R1a receptors on somatotrophs, stimulating GH release. GHRP-6 notably increases appetite via ghrelin-related pathways. Both act synergistically with GHRH analogues.
Growth Hormone-Releasing Peptides, specifically GHRP-2 and GHRP-6, are synthetic peptide compounds that have been widely investigated in preclinical research for their potential role in stimulating growth hormone release and modulating endocrine signaling pathways. These peptides are composed of short amino acid chains designed to interact with specific receptors involved in hormonal regulation, particularly within the hypothalamic-pituitary axis.
In controlled laboratory and animal-based models, GHRP-2 and GHRP-6 have been examined for their interaction with the growth hormone secretagogue receptor (GHS-R), a key component in the regulation of growth hormone secretion. Research has explored how these peptides may influence pulsatile hormone release, appetite-related signaling, and metabolic processes through receptor-mediated activity. Their structural design allows them to mimic endogenous signaling mechanisms associated with hormone regulation.
Beyond growth hormone-related pathways, investigations have also considered the potential influence of GHRP-2 and GHRP-6 on additional physiological systems, including energy balance, gastrointestinal signaling, and neuroendocrine communication. Some experimental findings suggest interactions with pathways linked to ghrelin activity, which may play a role in appetite regulation and metabolic feedback systems under controlled conditions.
To support consistency in experimental settings, both GHRP-2 and GHRP-6 are synthesized for laboratory use with standardized purity and stability. All findings referenced are derived exclusively from non-clinical research. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, ghrp-2 / ghrp-6 peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
GHRP-2 / GHRP-6 Peptide research is most relevant to protocols examining:
First-generation GHRP research and GHS-R1a receptor pharmacology
Appetite stimulation and metabolic studies (particularly GHRP-6)
Comparative research of GHRP selectivity profiles
Studies where cortisol/prolactin co-elevation is an acceptable variable
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~15–60 min). Review data, confirm baseline recovery before any repeat protocol.
Synthetic hexapeptides that mimic ghrelin and activate GHS-R1a receptors on somatotrophs, stimulating GH release. GHRP-6 notably increases appetite via ghrelin-related pathways. Both act synergistically with GHRH analogues.
| Parameter | Value |
|---|---|
| Dose range | 100–300 mcg/dose |
| Schedule | 1–3× daily |
| Route | Subcutaneous, Intranasal |
| Half-life | ~15–60 min |
especially GHRP-6 (ghrelin-mediated)
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
